Datapoint: Apellis Pharmaceuticals to Take on Alexion in PNH

The FDA on May 14 approved Apellis Pharmaceuticals’ Empaveli as a first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH), a rare and deadly chronic blood disorder. The biotech said it will initially target patients that have not responded to Soliris and/or Ultomiris, both C5 inhibitors from Alexion Pharmaceuticals. Under the pharmacy benefit, Soliris holds covered or better status for 53% of all covered lives. It is not covered for 26.3% of all lives.

SOURCE: MMIT Analytics, as of 5/19/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 24

Datapoint: Keytruda Scores Major Kidney Cancer Nod

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 23

Datapoint: Zing Health Acquires Lasso Healthcare

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 22

Datapoint: Paramount Loses Ohio Medicaid Battle

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today